公开(公告)号：US20070112396A1

公开(公告)日：2007-05-17

申请号：US11647208

申请日：2006-12-29

Applicant: James Dalton ,  Peter Single ,  David Money

Inventor： James Dalton ,  Peter Single ,  David Money

IPC: A61N1/00

CPC classification number: A61N1/3754 ,  A61N1/36036 ,  H01L2924/0002 ,  H01L2924/00

Abstract: A virtual wire assembly is disclosed. The assembly comprises a substantially electrically-nonconductive substrate; and a plurality of hermetic feedthroughs each comprising a conductive region extending transversely through the substrate to form a conductive pathway with accessible surfaces at opposing ends thereof, wherein each conductive pathway is electrically isolated from other conductive pathways. In certain embodiments of this aspect of the invention, the substantially electrically-nonconductive substrate is a semiconductor device, and the conductive regions each are comprised of an n-type or a p-type doped semiconductor material. Also disclosed are implanted medical devices requiring electronic or other components to be retained in a hermetic enclosure, such as cochlear and other sensory or neural prosthetic devices.

公开(公告)号：US20070042919A1

公开(公告)日：2007-02-22

申请号：US11207584

申请日：2005-08-19

Applicant: Catherine Schmit ,  James Dalton ,  Celeste Rosenberg

Inventor： Catherine Schmit ,  James Dalton ,  Celeste Rosenberg

IPC: A61K8/00

CPC classification number: C11D10/047

Abstract: Personal soap bar composition which give users enhanced skin feel benefits through an unexpected synergy between certain quaternary ammonium compounds and free fatty acids.

Abstract translation: 通过某些季铵化合物和游离脂肪酸之间的意想不到的协同作用，使用户增强皮肤感觉的个人皂条组合物。

公开(公告)号：US20060165068A1

公开(公告)日：2006-07-27

申请号：US11301637

申请日：2005-12-13

Applicant: James Dalton ,  Dmitry Isakbayev

Inventor： James Dalton ,  Dmitry Isakbayev

IPC: H04L12/66

CPC classification number: H04L12/14 ,  H04L12/1446 ,  H04L12/1471 ,  H04L29/12018 ,  H04L61/10 ,  H04L63/123 ,  H04L63/126 ,  H04L65/104 ,  H04L65/105 ,  H04L65/1069 ,  H04L65/1073 ,  H04L65/80 ,  H04L67/104 ,  H04M3/42008 ,  H04M7/0063 ,  H04M7/0078 ,  H04M15/56 ,  H04M2215/202

Abstract: A peering authority or settlement clearinghouse can be used to control access, collect session accounting information, and provide financial settlement of interconnect or session fees among anonymous Internet Protocol (IP) peers or networks. The addition of peering policy criteria, such as price and quality of service, to peer to peer route discovery mechanisms enable a trusted intermediary, such as the settlement clearinghouse, to authorize acceptable interconnection or peering sessions between anonymous IP peers. Any financial settlement transactions which result from the peering sessions may be subsequently executed by the settlement clearinghouse.

Abstract translation: 对等权力或结算清算所可用于控制访问，收集会话会计信息，并在匿名互联网协议（IP）对等体或网络之间提供互连或会话费用的财务结算。 将对等政策标准（如价格和服务质量）添加到对等路由发现机制中，使诸如结算信息交换中心之类的信任中介机构授权匿名IP对等体之间可接受的互连或对等会话。 结算交易所后期执行的任何金融结算交易可能随后由清算结算所执行。

公开(公告)号：US20060111441A1

公开(公告)日：2006-05-25

申请号：US11220414

申请日：2005-09-07

Applicant: James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka

Inventor： James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka

IPC: A61K31/277

CPC classification number: A61K31/277

Abstract: This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.

Abstract translation: 本发明提供：1）治疗患有肌肉消瘦障碍的受试者的方法; 2）预防受试者的肌肉消瘦障碍的方法; 3）治疗，预防，抑制，抑制或减轻患有肌肉消瘦障碍的受试者的肌肉损失的方法; 4）一种治疗，预防，抑制，减少或抑制患有肌肉消瘦障碍的受试者的肌肉消瘦的方法; 和/或5）通过向受试者施用选择性雄激素受体调节剂（SARM）和/或类似物衍生物，治疗，预防，抑制，减少或抑制患有肌肉消瘦疾病的受试者的肌肉蛋白分解代谢的方法 ，所述SARM化合物的异构体，代谢物，药学上可接受的盐，药物产品，水合物，N-氧化物，前药，多晶型物，杂质或晶体，或其任何组合。

公开(公告)号：US20060040998A1

公开(公告)日：2006-02-23

申请号：US10992175

申请日：2004-11-18

Applicant: Duane Miller ,  Veeresa Gududuru ,  James Dalton ,  Eunju Hurh

Inventor： Duane Miller ,  Veeresa Gududuru ,  James Dalton ,  Eunju Hurh

IPC: A61K31/427 ,  C07D417/02

CPC classification number: C07D277/06 ,  C07D277/14 ,  C07D277/20 ,  C07D277/34 ,  C07D277/56 ,  C07D417/04

Abstract: Substituted thiazolidinone carboxylic acid amides and substituted thiazolidine carboxylic acid amides according to formulae (I) and (II) are disclosed where the various substituent groups are as defined in the specification. Methods of making these compounds, pharmaceutical compositions containing the compounds, and their use, particularly for treating or preventing cancer, are also disclosed.

Abstract translation: 公开了根据式（I）和（II）的取代的噻唑烷酮羧酸酰胺和取代的噻唑烷羧酸酰胺，其中各种取代基如说明书中所定义。 还公开了制备这些化合物的方法，含有这些化合物的药物组合物及其用途，特别是用于治疗或预防癌症的方法。

公开(公告)号：US20060035966A1

公开(公告)日：2006-02-16

申请号：US10995567

申请日：2004-11-24

Applicant: James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka ,  Leonid Kirkovsky ,  Dong Hwang ,  Arnab Mukherjee

Inventor： James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka ,  Leonid Kirkovsky ,  Dong Hwang ,  Arnab Mukherjee

IPC: C07C331/28

CPC classification number: C07C323/60 ,  A61K31/16 ,  A61K31/26 ,  A61K31/275 ,  C07C261/02 ,  C07C265/12 ,  C07C331/10 ,  C07C331/28

Abstract: In one embodiment, this invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). The SARM compounds have unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. In one embodiment, the SARM compounds bind irreversibly to the androgen receptor In another embodiment, the SARM compounds are androgen receptor antagonists, which bind irreversibly to the androgen receptor. In another embodiment, the SARM compounds are alkylating agents. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.

Abstract translation: 在一个实施方案中，本发明提供了一类雄激素受体靶向剂（ARTA）。 这些药剂定义了一种新的化合物亚类，它们是选择性雄激素受体调节剂（SARM）。 SARM化合物对雄激素受体的非甾体配体具有意想不到的抗雄激素活性。 在一个实施方案中，SARM化合物不可逆地与雄激素受体结合。在另一个实施方案中，SARM化合物是雄激素受体拮抗剂，其不可逆地结合雄激素受体。 在另一个实施方案中，SARM化合物是烷化剂。 SARM化合物，单独或作为组合物，可用于a）男性避孕; b）治疗各种激素相关病症，例如与老年雄性雄激素降低有关的病症（ADAM），如疲劳，抑郁，性欲降低，性功能障碍，勃起功能障碍，性腺机能减退，骨质疏松症，脱发，贫血， 肥胖，肌营养不良，骨质减少，骨质疏松症，良性前列腺增生，情绪和认知和前列腺癌的改变; c）治疗与男性雄激素降低相关的病症（ADIF），如性功能障碍，性欲降低，性腺机能减退，肌营养不良，骨质减少，骨质疏松症，认知和情绪改变，抑郁症，贫血，脱发，肥胖，子宫内膜异位症，乳腺癌 癌症，子宫癌和卵巢癌; d）治疗和/或预防急性和/或慢性肌肉消瘦病症; e）预防和/或治疗干眼症状; f）口服雄激素替代疗法; g）降低前列腺癌的发生率，停止或导致消退; 和/或h）诱导癌细胞中的细胞凋亡。

公开(公告)号：US20060004042A1

公开(公告)日：2006-01-05

申请号：US11029022

申请日：2005-01-05

Applicant: James Dalton ,  Duane Miller ,  Karen Veverka

Inventor： James Dalton ,  Duane Miller ,  Karen Veverka

IPC: A61K31/4706 ,  A61K31/405 ,  A61K31/165

CPC classification number: A61K31/165 ,  A61K31/4706

Abstract: The present invention relates to pharmaceutical compositions and formulations comprising a novel class of androgen receptor targeting agents (ARTA) which demonstrate androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. The agents define a new subclass of compounds which are selective androgen receptor modulators (SARM) which are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of chronic muscular wasting; and/or e) decreasing the incidence of, halting or causing a regression of prostate cancer. The present invention provides pharmaceutical compositions comprising the selective androgen receptor modulator compounds, together with pharmaceutically acceptable excipients.

Abstract translation: 本发明涉及包含新型雄激素受体靶向剂（ARTA）的药物组合物和制剂，其表现出雄激素受体的非甾体配体的雄激素和合成代谢活性。 这些药剂定义了一种新的选择性雄激素受体调节剂（SARM）的化合物亚类，它们可用于a）男性避孕; b）治疗各种激素相关病症，例如与老年雄性雄激素降低有关的病症（ADAM），如疲劳，抑郁，性欲降低，性功能障碍，勃起功能障碍，性腺机能减退，骨质疏松症，脱发，贫血， 肥胖，肌营养不良，骨质减少，骨质疏松症，良性前列腺增生，情绪和认知和前列腺癌的改变; c）治疗与男性雄激素降低相关的病症（ADIF），如性功能障碍，性欲降低，性腺机能减退，肌营养不良，骨质减少，骨质疏松症，认知和情绪改变，抑郁症，贫血，脱发，肥胖，子宫内膜异位症，乳腺癌 癌症，子宫癌和卵巢癌; d）治疗和/或预防慢性肌肉消瘦; 和/或e）降低前列腺癌的发生率，停止或导致消退。 本发明提供了包含选择性雄激素受体调节剂化合物以及药学上可接受的赋形剂的药物组合物。

公开(公告)号：US20050080055A1

公开(公告)日：2005-04-14

申请号：US10760152

申请日：2004-01-20

Applicant: James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka

Inventor： James Dalton ,  Duane Miller ,  Mitchell Steiner ,  Karen Veverka

IPC: A61K20060101 ,  A61K31/165 ,  A61K31/21 ,  A61K31/26 ,  A61K31/277 ,  A61K31/32 ,  A61K31/66 ,  A61P35/00

CPC classification number: A61K31/66 ,  A61K31/21 ,  A61K31/26

Abstract: This invention relates to the prevention and treatment of breast cancer in a subject, for example a female subject. Accordingly, this invention provides methods of a) treating a subject suffering from breast cancer; b) preventing, suppressing, inhibiting or reducing the incidence of breast cancer in a subject; c) delaying the progression of breast cancer in a subject suffering from breast cancer; d) preventing the recurrence of breast cancer in a subject; e) treating the recurrence of breast cancer in a subject suffering from breast cancer; and/or f) treating, preventing, suppressing or inhibiting metastasis in a subject suffering from breast cancer, by administering to the subject a therapeutically effective amount of an Androgen Receptor Antagonist and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, crystal, polymorph, prodrug or any combination thereof, as described herein.

Abstract translation: 本发明涉及预防和治疗受试者，例如女性受试者的乳腺癌。 因此，本发明提供了a）治疗患有乳腺癌的受试者的方法; b）预防，抑制，抑制或降低患者乳腺癌的发生率; c）延缓乳腺癌患者乳腺癌的进展; d）预防受试者乳腺癌的复发; e）治疗乳腺癌患者乳腺癌的复发; 和/或f）通过向受试者施用治疗有效量的雄激素受体拮抗剂和/或其类似物，衍生物，异构体，代谢物，药学上可接受的盐，治疗，预防，抑制或抑制患有乳腺癌的受试者的转移 ，药物产品，水合物，N-氧化物，晶体，多晶型物，前药或其任何组合。

公开(公告)号：US20050038110A1

公开(公告)日：2005-02-17

申请号：US10863524

申请日：2004-06-09

Applicant: Mitchell Steiner ,  James Dalton ,  Duane Miller ,  Karen Veverka

Inventor： Mitchell Steiner ,  James Dalton ,  Duane Miller ,  Karen Veverka

IPC: A61K31/277 ,  A61K31/32 ,  C07F7/24

CPC classification number: C07C255/60 ,  C07C235/24 ,  C07C255/54

Abstract: This invention provides a class of androgen receptor targeting agents. The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM).

Abstract translation: 本发明提供一类雄激素受体靶向剂。 这些药剂定义了一种新的化合物亚类，它们是选择性雄激素受体调节剂（SARM）。

公开(公告)号：US6074998A

公开(公告)日：2000-06-13

申请号：US12990

申请日：1998-01-26

Applicant: Mengtao He ,  Michael Barratt ,  James Dalton ,  Michael Fair ,  Michael Petko ,  John Sheehan ,  Abid Khan-Lodhi

Inventor： Mengtao He ,  Michael Barratt ,  James Dalton ,  Michael Fair ,  Michael Petko ,  John Sheehan ,  Abid Khan-Lodhi

IPC: A61K8/37 ,  A61K8/86 ,  A61Q19/10 ,  C11D3/18 ,  C11D3/20 ,  C11D3/37 ,  C11D17/00 ,  A61K7/50

CPC classification number: A61K8/375 ,  A61K8/86 ,  A61Q19/10 ,  C11D17/006 ,  C11D3/18 ,  C11D3/2003 ,  C11D3/2065 ,  C11D3/2093 ,  C11D3/3707 ,  C11D3/373 ,  C11D3/3738 ,  C11D3/2024 ,  C11D3/2044 ,  C11D3/2051

Abstract: The present invention relates to solid detergent compositions generally comprising anionic/amphoteric/nonionic surfactant systems. Addition of specific polyol esters wherein the melting temperature and HLB are specifically defined has been found to remarkably enhance the oil/humectant structuring and releasing capabilities of a skin cleansing bar. In a second embodiment, the invention relates to a method for enhancing the bar's capability of including high levels of oil and/or humectant by carefully balancing the polyol ester's weight ratio to the oil and/or humectant. In the third embodiment, the invention relates to a method of enhancing the bar's capability of incorporating high levels of oil and/or humectant and delivering the oil and/or humectant for skin benefit by carefully balancing the polyol ester's weight ratio to the other costructurants such as PEG 8000 and fatty acid. In the third embodiment, skin mildness and especially skin moisturization are significantly enhanced by the detergent bar compositions comprising the combination of the specific polyol ester with oil and/or humectant.

Abstract translation: 本发明涉及通常包含阴离子/两性/非离子表面活性剂体系的固体洗涤剂组合物。 已经发现加入特定的多元醇酯，其中熔融温度和HLB被特别限定，显着增强了皮肤清洁条的油/保湿剂结构和释放能力。 在第二个实施方案中，本发明涉及通过将多元醇酯的重量比与油和/或湿润剂仔细平衡来提高棒的包含高含量油和/或湿润剂的能力的方法。 在第三个实施方案中，本发明涉及通过仔细地将多元醇酯的重量比与其它共同结构化剂进行平衡来提高棒的掺入高水平的油和/或湿润剂并递送油和/或保湿剂以获得皮肤益处的方法， 如PEG 8000和脂肪酸。 在第三个实施方案中，通过包含特定多元醇酯与油和/或湿润剂的组合的洗涤剂棒组合物，皮肤温和性，特别是皮肤保湿显着增强。